pp-245 Tablets
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Progressive and tophaceous gout / Clinical stage: Phase 3 / Modality: URAT1 inhibitor (next-generation urate-lowering agent) / Mechanism & Target: URAT1 transporter inhibition / Route & form: Oral, once-daily dosing / Differentiation: Next-generation URAT1 inhibitor; two fully recruited Phase 3
Manufacturer #6157
| Specialty biopharmaceutical company focused on rare hematological, immunological, and inflammatory diseases. Develops targeted biologics and small molecules for high unmet medical need conditions. Advances Phase 3 programs through a global development and commercialization network. |
None